<DOC>
	<DOC>NCT01097616</DOC>
	<brief_summary>This is a multicenter study to test the hypothesis that suvorexant (MK-4305) is superior to placebo in improving insomnia as measured by change from baseline in: subjective total sleep time and time to sleep onset, wake time after persistent sleep onset, and latency to onset of persistent sleep. Participants who complete the initial 3-month Treatment (TRT) Phase may participate in an optional 3-month Extension (EXT) Phase.</brief_summary>
	<brief_title>Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>Must be ≥18 yrs old on the day of signing informed consent Diagnosed with Primary Insomnia Good physical and mental health Participant ≥65 yrs old score at least 25 on the Mini Mental State Examination A female participant who is of reproductive potential has a negative serum pregnancy test and agrees to use contraception Reports difficulty with initiating and maintaining sleep during the 4 weeks prior to Visit 1 (accordingly to specific protocol criteria) Reports spending 6.5 to 9 hours nightly in bed on at least 3 out of 7 nights prior to Visit 1 Regular bedtime is between 9 pm1 am Willing to refrain from napping while in study Able to read, understand and complete questionnaires and all diaries Willing to limit alcohol, caffeine, and nicotine consumption while in the study For a portion of participants: Must be willing to stay overnight in a sleep laboratory and must be willing to stay in bed for at least 8 hours each night while at the sleep laboratory Female participant is pregnant and/or breastfeeding at Prestudy visit, or expecting to conceive while in study History or diagnosis of another sleep disorder Difficulty sleeping due to a medical condition History of a neurological disorder History of bipolar disorder, psychotic disorder, or posttraumatic stress disorder, or current psychiatric disorder that requires a prohibited medication Ongoing depression History of substance abuse or dependence History or current evidence of a clinically significant cardiovascular disorder or clinically significant electrocardiogram (ECG) at Prestudy Visit Taking certain prohibited medications Consumption of the equivalent of &gt;15 cigarettes a day History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer Participant is considered morbidly obese Previously randomized in another investigational study of suvorexant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>